Upon completing his undergraduate degree in 1985, Meyerson spent a year in Japan at the University of Kyoto before beginning began medical school.
[5] During his third year at Harvard Medical School, while doing a rotation at Massachusetts General Hospital (MGH), he became interested in molecular biology revolution and cancer research.
[9] Meyerson joined the faculty at the Dana–Farber Cancer Institute (DFCI) in 1998 where he continued to focus on using genomic approaches to understand the biology and genetics of human lung carcinomas.
[10] Following this development, Meyerson collaborated with fellow Harvard researchers to identify mutations in lung cancer that could be targeted therapeutically.
The scientists found that patients whose lung cancers harbor a malfunctioning version of EGFR protein responded well to the drug gefitinib.
[16] Two years later, Meyerson was the recipient of the 2016 Han-Mo Koo Memorial Award for his contributions to the understanding of cancer genomics and targeted therapies.